Latest Insider Transactions at Bei Gene, Ltd. (BGNE)
This section provides a real-time view of insider transactions for Bei Gene, Ltd. (BGNE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BeiGene, Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BeiGene, Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 24
2025
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
2,007
-65.73%
|
$531,855
$265.81 P/Share
|
Jun 23
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
1,028
-100.0%
|
$267,280
$260.0 P/Share
|
Jun 23
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,174
-98.42%
|
$831,588
$262.24 P/Share
|
Jun 23
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
1,363
-100.0%
|
$354,380
$260.0 P/Share
|
Jun 17
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
470
-100.0%
|
$117,970
$251.37 P/Share
|
Jun 17
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,460
-100.0%
|
$373,760
$256.49 P/Share
|
Jun 17
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
630
-100.0%
|
$157,500
$250.87 P/Share
|
Jun 16
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
1,177
-71.46%
|
$313,082
$266.4 P/Share
|
Jun 16
2025
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
422
-100.0%
|
$112,252
$266.5 P/Share
|
Jun 16
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,680
-71.6%
|
$978,880
$266.05 P/Share
|
Jun 16
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
1,543
-40.05%
|
$408,895
$265.85 P/Share
|
Jun 11
2025
|
Titus B. Ball Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
134
-100.0%
|
$34,572
$258.36 P/Share
|
Jun 10
2025
|
Titus B. Ball Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,601
+28.58%
|
-
|
Jun 10
2025
|
Aaron Rosenberg Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,674
+21.62%
|
-
|
Jun 10
2025
|
Chan Henry Lee SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
46,878
+14.17%
|
-
|
Jun 10
2025
|
Xiaobin Wu President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
123,370
+8.83%
|
-
|
Jun 10
2025
|
Lai Wang Global Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
86,359
+7.54%
|
-
|
Jun 10
2025
|
John Oyler Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
185,055
+2.19%
|
-
|
Jun 10
2025
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
41,760
-63.28%
|
$10,982,880
$263.1 P/Share
|
Jun 10
2025
|
Xiaodong Wang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,760
+50.0%
|
$250,560
$6.5 P/Share
|
Jun 10
2025
|
Xiaodong Wang Director |
BUY
Grant, award, or other acquisition
|
Direct |
98,696
+1.87%
|
-
|
Jun 10
2025
|
Qingqing Yi Director |
SELL
Other acquisition or disposition
|
Direct |
29,614
-52.01%
|
-
|
Jun 06
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
1,934
-51.01%
|
$489,302
$253.43 P/Share
|
Jun 06
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
1,402
-54.5%
|
$353,304
$252.77 P/Share
|
Jun 06
2025
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
700
-83.57%
|
$179,200
$256.29 P/Share
|
Jun 06
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,127
-55.54%
|
$1,297,131
$253.38 P/Share
|
May 21
2025
|
Qingqing Yi Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,985
+16.17%
|
-
|
May 21
2025
|
Alessandro Riva Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,985
+16.17%
|
-
|
May 21
2025
|
Olivier Brandicourt Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,985
+28.67%
|
-
|
May 21
2025
|
Shalini Sharp Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,985
+36.47%
|
-
|
May 21
2025
|
Anthony C Hooper Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,985
+14.51%
|
-
|
May 21
2025
|
Corazon (Corsee) D. Sanders Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,985
+16.1%
|
-
|
May 21
2025
|
Margaret Dugan Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,985
+16.17%
|
-
|
May 21
2025
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
43,940
+12.92%
|
-
|
May 13
2025
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
41,760
-72.47%
|
$9,354,240
$224.06 P/Share
|
May 13
2025
|
Xiaodong Wang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,760
+50.0%
|
$250,560
$6.5 P/Share
|
May 09
2025
|
John Oyler Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,990,603
-19.6%
|
$33,840,251
$17.85 P/Share
|
May 09
2025
|
John Oyler Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,055,415
+28.54%
|
$0
$0.5 P/Share
|
Apr 14
2025
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
41,760
-34.46%
|
$10,147,680
$243.52 P/Share
|
Apr 14
2025
|
Xiaodong Wang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,760
+50.0%
|
$250,560
$6.5 P/Share
|
Apr 01
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
51,921
-62.98%
|
$14,641,722
$282.13 P/Share
|
Apr 01
2025
|
Xiaobin Wu President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
51,921
+45.29%
|
$7,632,387
$147.19 P/Share
|
Mar 18
2025
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
41,760
-44.49%
|
$10,899,360
$261.12 P/Share
|
Mar 18
2025
|
Xiaodong Wang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,760
+50.0%
|
$250,560
$6.5 P/Share
|
Mar 14
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
Mar 11
2025
|
Xiaodong Wang Director |
SELL
Bona fide gift
|
Direct |
158,717
-3.03%
|
-
|
Mar 10
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
41,210
-39.18%
|
$9,972,820
$242.91 P/Share
|
Mar 10
2025
|
John Oyler Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,210
+50.0%
|
$247,260
$6.5 P/Share
|
Mar 10
2025
|
John Oyler Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
497,822
+7.55%
|
$0
$0.5 P/Share
|
Mar 07
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
58,590
-32.93%
|
$14,647,500
$250.34 P/Share
|